Description
ADCC-Enhanced anti-Neuropeptide W (3A1A) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Infertility; Renal edema; Digestive Ulcer; Gastric Hyperacidity
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Neuropeptide W antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
The product of this gene is processed into 23- and 30-amino acid neuropeptides that bind and activate two G-protein coupled receptors in the central nervous system. The neuropeptides have been shown to enhance cortisol secretion from adrenal cells through the adenylate cyclase/protein kinase A signaling cascade. The preproprotein is translated using a non-AUG initiation codon that is inferred from analyses of the mouse ortholog. [provided by RefSeq, Jul 2008]
Alternative Names
neuropeptide W
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with NPW include Neurodegeneration With Brain Iron Accumulation 6 and Schimmelpenning-Feuerstein-Mims Syndrome.
Related Pathways
Its related pathways are Signaling by GPCR and Peptide ligand-binding receptors.
Function
It regulates the organization of neuroendocrine signals entering the anterior pituitary gland. Stimulate drinking water and food intake. May play a role in the response of the hypothalamus to stress (through similarity). NPW23 activates GPR7 and GPR8 more effectively than NPW30.
Post-translational modifications
1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
The antibody specifically reacts with a partial peptide at the N-terminal region or the C-terminal region of NPW, which enables to quantify NPW with highly sensitivity and specifically. Moreover, this antibody is useful as an agent for preventing/treating infertility, renal edema, digestive ulcer, gastric hyperacidity, etc., and a diagnostic for these diseases.
Antibody Indication
Infertility; Renal edema; Digestive Ulcer; Gastric Hyperacidity
